logo
Earnings To Watch: Preferred Bank (PFBC) Reports Q2 Results Tomorrow

Earnings To Watch: Preferred Bank (PFBC) Reports Q2 Results Tomorrow

Yahoo5 days ago
Commercial banking company Preferred Bank (NASDAQ:PFBC) will be announcing earnings results this Monday before market open. Here's what investors should know.
Preferred Bank missed analysts' revenue expectations by 5.5% last quarter, reporting revenues of $66.66 million, down 6.9% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' net interest income estimates and a miss of analysts' EPS estimates.
Is Preferred Bank a buy or sell going into earnings? Read our full analysis here, it's free.
This quarter, analysts are expecting Preferred Bank's revenue to grow 1.9% year on year to $70.82 million, a reversal from the 9% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.43 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Preferred Bank has missed Wall Street's revenue estimates three times over the last two years.
Looking at Preferred Bank's peers in the regional banks segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Texas Capital Bank delivered year-on-year revenue growth of 15.2%, beating analysts' expectations by 2.7%, and Nicolet Bankshares reported revenues up 12.7%, topping estimates by 4.4%. Texas Capital Bank traded up 4.8% following the results while Nicolet Bankshares was also up 7.8%.
Read our full analysis of Texas Capital Bank's results here and Nicolet Bankshares's results here.
There has been positive sentiment among investors in the regional banks segment, with share prices up 10.3% on average over the last month. Preferred Bank is up 13.8% during the same time and is heading into earnings with an average analyst price target of $93.75 (compared to the current share price of $92.61).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Coinbase Global (COIN): 'For All I Know It's A Pump And Dump, I Don't See Anybody Dumping?' Says Jim Cramer
Coinbase Global (COIN): 'For All I Know It's A Pump And Dump, I Don't See Anybody Dumping?' Says Jim Cramer

Yahoo

time3 minutes ago

  • Yahoo

Coinbase Global (COIN): 'For All I Know It's A Pump And Dump, I Don't See Anybody Dumping?' Says Jim Cramer

We recently published . ABC is one of the stocks Jim Cramer recently discussed. Coinbase Global, Inc. (NASDAQ:COIN) is a cryptocurrency exchange whose 57% year-to-date share price gain has resulted from legislation benefiting stablecoins and the bullish run in Bitcoin. Cramer's previous comments about Coinbase Global, Inc. (NASDAQ:COIN) asserted that the firm has benefited from its large market share. This time, he discussed Coinbase Global, Inc. (NASDAQ:COIN)'s valuation: '[On Cantor going to $500] I think that's within reason. PE's of these companies, this is the lowest one in park, at 40 times earnings, well Robinhood's not that low yet, I mean not that high. I mean People have to understand P/E analysis is not working. Robinhood's at 62 times earnings. COIN is at 40 times earnings. And people will say, uh, Jim, the multiple's too high. And I come back and say, do you really think the retail investor knows what a multiple is? Like what are you like, some sort of abstraction? See, this is a new world. I'm realistic. Look, for all I know it's a pump and dump, I don't see anybody dumping? I'll tell you when it's over. When the insiders do big deals and sell. And when there's secondaries. And there haven't been. That's what caused 2014. That's what caused it to end. 2020. That's what caused it to end. I mean, 2000. That's what caused it. 2000 being the vicious number of secondaries between January and March of 2021 and also about 2020. These years were just horrendous. And these companies broke down. I'm waiting for that. But it's not happening. So I wanna give people my history. Which is that it should have happened by now. Like Karp should have been selling and the companies should have been raising money. But they don't need to. These companies are incredibly well capitalized. And when people want to try and say, you know what they're like what happened to the dotcoms, I remember the dotcoms. They didn't have any money.' While we acknowledge the potential of COIN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.

Files.com Acquires ExpanDrive, Launches Free Version to Expand Multi-Cloud Access
Files.com Acquires ExpanDrive, Launches Free Version to Expand Multi-Cloud Access

Yahoo

time3 minutes ago

  • Yahoo

Files.com Acquires ExpanDrive, Launches Free Version to Expand Multi-Cloud Access

TEMPE, Ariz., July 24, 2025--(BUSINESS WIRE)-- the leading platform for secure and automated file transfer, today announced its acquisition of ExpanDrive, a desktop application for accessing cloud and remote storage as local drives. As part of the acquisition, ExpanDrive is now free for personal use under a new freemium pricing model. Bringing Remote Storage to the Desktop ExpanDrive enables users to mount cloud platforms and remote servers – including SFTP, Amazon S3, Google Drive, and Dropbox – directly into their native file explorers on macOS, Windows, and Linux, without syncing or separate transfers. "ExpanDrive offers a beautifully simple way to access remote storage right from your desktop," said Kevin Bombino, CEO of "We're thrilled to make it free for personal use, helping more people experience frictionless file access." Freemium Model Now Live ExpanDrive is now: Free for individuals and small teams (under 10 users annually) Paid for larger teams and enterprises, unlocking features like the Web Console, Server Edition, and premium support Strengthening the Ecosystem ExpanDrive's technology and user experience will help shape future innovations across the platform – reinforcing its mission to unify secure file access, automation, and management at any scale. About ExpanDrive Founded in 2004, ExpanDrive allows users to mount cloud and remote storage as local drives across operating systems, simplifying access to services like SFTP, S3, Google Drive, Dropbox, and more. About is the secure file platform for automation, compliance, and scale, trusted by over 4,000 organizations. It enables teams to manage, transfer, and integrate files across systems with enterprise-grade security, direct cloud integrations, and powerful automation. View source version on Contacts Media ContactTom SnyderMarketing Director, (520) 231-6027 ext.

Knee Replacement Surgery Market worth $16.17 billion in 2030 with 6.1% CAGR
Knee Replacement Surgery Market worth $16.17 billion in 2030 with 6.1% CAGR

Yahoo

time3 minutes ago

  • Yahoo

Knee Replacement Surgery Market worth $16.17 billion in 2030 with 6.1% CAGR

DELRAY BEACH, Fla., July 24, 2025 /PRNewswire/ -- The global Knee Replacement Surgery Market, valued at US$10.86 billion in 2023 stood at US$12.00 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$16.17 billion by the end of the period. The key factor propelling the market is the increasing prevalence of osteoarthritis, particularly among the aging population. This increase in cases is driving a higher demand for surgical interventions, including total and partial knee replacements. As life expectancy increases and age-associated degenerative changes to the knee joint become more pronounced, the necessity for these procedures is escalating. This demographic shift is a significant catalyst for market expansion, contributing to a growing global patient population requiring knee treatment solutions. Download PDF Brochure: Browse in-depth TOC on "Knee Replacement Surgery Market" 300 - Tables55 - Figures400 - Pages By product, the global knee replacement surgery market is segmented into knee implants, knee braces & support systems, and orthobiologics. The orthobiologics segment is expected to register significant growth over the forecast period. A growing number of patients are opting for non-surgical interventions to manage their conditions. Orthobiologics, such as Platelet-Rich Plasma (PRP) therapy, stem cell treatments, and hyaluronic acid injections, provide less invasive alternatives that enhance healing and stimulate tissue regeneration. These modalities are particularly beneficial for patients with early to moderate osteoarthritis, where conventional surgical interventions may be premature or unnecessary. By application, the global knee replacement surgery market is segmented into osteoarthritis & rheumatoid arthritis, degenerative disease, cancer, and other applications. The Centers for Disease Control and Prevention (CDC) reports that approximately 319,000 individuals aged 65 and older are hospitalized annually in the United States due to hip fractures. Surgical intervention typically involves the use of fixation devices that stabilize the fractured bone by immobilizing it, thereby providing a protective framework that facilitates healing. The incorporation of orthobiologics into orthopedic procedures is gaining traction, as these biological agents enhance the regenerative capacity of tissues and promote faster recovery. With the increasing prevalence of conditions such as rheumatoid arthritis and osteoarthritis, coupled with a growing geriatric population, there is a projected surge in the adoption of knee surgery devices to address these joint pathologies effectively. By end user, the end user segment of the knee replacement surgery market includes hospitals, ambulatory surgery centers, and orthopedic clinics. In 2024, hospitals accounted for the largest market share. Recent advancements in surgical technologies, anesthesia techniques, and shifts in Medicare reimbursement policies have driven an escalation in orthopedic procedures within outpatient environments, particularly ambulatory surgery centers. These developments are poised to significantly enhance the expansion of the ASC market. Consequently, we can anticipate a marked increase in the volume of knee arthroplasties conducted in these settings, thereby further propelling the growth of the ASC segment in the near future. Request Sample Pages : As of 2024, prominent players in the knee replacement surgery market are Zimmer Biomet (US), Stryker (US), Johnson & Johnson, Inc. (US), Smith+Nephew PLC (UK), and B. Braun (Germany). Stryker (US): Stryker ranks among the top firms in the global knee replacement surgery market. The organization has established a formidable presence in the global market, extending its operational reach across key regions, including Europe, North America, the Middle East, Africa, and the Asia Pacific. With a successful track record in more than 75 countries, the company has effectively built a strong brand recognition, particularly through its Orthopedics division, which specializes in advanced surgical devices for knee treatments. Driven by a commitment to growth, the firm continuously seeks to broaden its product portfolio, ensuring that it remains at the forefront of innovation by launching groundbreaking solutions tailored to meet the evolving demands of the market. To maintain its competitive advantage, the organization places a high priority on innovation and the creation of unique, differentiated products that stand out in an increasingly crowded marketplace. A central element of its strategy is a substantial investment in R&D, which fuels the introduction of pioneering technologies. These advancements are specifically designed to address the pressing, unmet needs of healthcare providers and patients, thereby enhancing treatment outcomes and improving the quality of care within the healthcare system. Zimmer Biomet (US) Zimmer Biomet (US) is among the leading companies in the global knee replacement surgery market. The firm is a key player in the healthcare industry, specializing in the production and distribution of a diverse range of medical devices and healthcare products designed to meet various medical needs. With a robust presence across multiple international markets, the company operates in notable countries such as Germany, where it taps into a highly developed healthcare system; France, which is known for its emphasis on innovation in medicine; and Italy, which has a rich history of medical advancements. In addition to these European nations, the firm's influence extends to Switzerland, renowned for its high-quality healthcare, as well as Spain and the UK, both of which represent significant markets for medical technology. The firm also maintains a strong foothold in Asia, including major economies such as Japan and South Korea, which are recognized for their cutting-edge healthcare technologies. Further expanding its global reach, the firm has established a presence in China, one of the fastest-growing healthcare markets in the world, as well as in Australia and New Zealand, where it provides vital healthcare solutions. The company is also active in Taiwan, India, Hong Kong, Thailand, Singapore, and Malaysia, where it meets the diverse medical needs of these dynamic populations. To support its extensive operations, the firm has developed a comprehensive distribution network that spans Benelux (Belgium, Netherlands, and Luxembourg) and the Nordic countries, ensuring effective market penetration in Central and Eastern Europe. Additionally, the firm has made significant inroads in the Middle East and Africa, regions that are increasingly recognizing the importance of advanced medical technology in improving healthcare outcomes. This strategic global presence not only enhances the firm's competitiveness but also reinforces its commitment to advancing healthcare worldwide. Johnson & Johnson Services, Inc. (US) Johnson & Johnson Services, Inc. (US) is a prominent entity within the knee replacement surgery sector, engaged in the comprehensive manufacturing, R&D, and global marketing of joint replacement technologies and related healthcare products. Operating under the MedTech business segment, it specializes in advancing knee replacement surgery products aimed at improving clinical outcomes through innovative technology. In a strategic collaboration with CrossRoads Extremity Systems (US), the company is focused on enhancing orthopedic care by integrating novel ideas to provide patients with superior health benefits. The firm commands a substantial market share across more than 60 countries, spanning multiple regions, including Asia Pacific, North America, the Middle East & Africa, and Europe. Additionally, it operates through a robust portfolio of key subsidiaries, which includes DePuy, Inc. (US), Animas Corporation (US), Ethicon, Inc. (US), and LifeScan, Inc. (US). For more information, Inquire Now! Related Reports: Joint Replacement Devices Market Orthopedic Braces & Supports Market Medical Robots Market Surgical Robots Market Minimally Invasive Surgical Instruments Market Get access to the latest updates on Knee Replacement Surgery Companies and Knee Replacement Surgery Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store